AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Lupus

Recent research efforts aimed at curing Lupus.

Last updated
Also available in
Français — Lupus

Lupus

Overview

Lupus is a group of autoimmune diseases in which the immune system attacks the body’s own tissues. This report focuses on systemic lupus erythematosus (SLE), the form that can affect the skin, joints, blood cells, kidneys, brain, lungs, heart, and other organs. It most often affects women, can begin at many ages, and varies greatly between people; some have intermittent rashes, pain, and fatigue, while others develop life-threatening organ inflammation such as lupus nephritis, a kidney complication. Modern treatment has substantially improved outcomes, but lupus remains a chronic disease with risks from persistent inflammation, organ damage, infection, and treatment toxicity. EULAR SLE management recommendations

Current care aims for remission or low disease activity rather than cure. Standard treatment generally includes hydroxychloroquine, short and progressively minimized courses of corticosteroids, and—depending on organ involvement—immunosuppressants such as mycophenolate, azathioprine, methotrexate, cyclophosphamide, calcineurin inhibitors, and targeted biologics including belimumab or anifrolumab. EULAR SLE management recommendations These treatments can prevent flares and organ damage, but many patients require long-term medication and some remain treatment-refractory.

Scope of Recent Research (2020–present)

Research since 2020 has been unusually active, with the central curative question shifting from “How can lupus inflammation be suppressed?” to “Can the immune system be durably reset or retrained so that it stops attacking self?” The leading clinical strategy is deep depletion of disease-driving B cells using CD19-directed chimeric antigen receptor (CAR) T cells, while laboratory programs are pursuing more selective approaches that spare healthy immunity, including dual-target CAR-T cells, CAR natural-killer cells, chimeric autoantibody receptor T cells, and antigen-specific regulatory T cells. Early results are striking but still derive largely from small, uncontrolled studies; no therapy has yet demonstrated that it cures lupus in the regulatory sense. CD19 CAR-T case series CASTLE phase 1/2 trial

Major Breakthroughs and Emerging Therapies

The most important breakthrough is CD19 CAR-T-cell therapy, an individualized treatment in which a patient’s T cells are collected, genetically equipped to recognize CD19 on B cells, expanded, and reinfused after temporary immune-cell-lowering chemotherapy. The rationale is that removing both circulating and tissue-resident B cells may eliminate the immune “memory” that produces harmful autoantibodies, after which a healthier B-cell compartment can regrow. In the first 2022 report, five people with severe, treatment-refractory SLE entered drug-free remission after CD19 CAR-T therapy despite later B-cell return. First anti-CD19 CAR-T study in refractory SLE A subsequent 15-person autoimmune case series included eight people with SLE; patients were able to discontinue immunosuppressive medicines, with follow-up extending to 29 months. CD19 CAR-T case series

The approach has now been reproduced in prospective studies. The CASTLE phase 1/2a basket study evaluated autologous CD19 CAR-T cells in severe refractory SLE, systemic sclerosis, and inflammatory myositis. Across 24 treated participants, the investigators reported no disease relapses during a median 13 months of follow-up and no reintroduction of immunosuppressants or glucocorticoids; however, the study was small, nonrandomized, and included several autoimmune diseases rather than SLE alone. CASTLE phase 1/2 trial A separate phase 1 study of the commercial CD19 CAR-T product relmacabtagene autoleucel reported that four of eight participants with active SLE met DORIS remission criteria and seven reached low disease activity within one to four months. Relma-cel phase 1 SLE trial

A second strategy aims to make immune resetting more complete by attacking both CD19-positive B cells and BCMA-positive long-lived plasma cells, the antibody-secreting cells that may survive conventional B-cell depletion. In an ongoing phase 1 study of co-infused anti-CD19 and anti-BCMA CAR-T products, 12 of 15 people with treatment-refractory SLE met both low-disease-activity and DORIS-remission criteria by week 12, with no dose-limiting toxicities reported over a median 712 days of follow-up. Dual CD19/BCMA CAR-T phase 1 trial This is a compelling proof of concept, but it remains early clinical evidence rather than confirmation of a cure.

Researchers are also trying to replace broad immune ablation with precision tolerance therapies. One preclinical approach engineers regulatory T cells—immune cells that normally restrain harmful responses—to recognize the Smith (Sm) autoantigen, a lupus-associated target. In a humanized mouse model of lupus nephritis, Sm-specific regulatory T cells reduced kidney injury more effectively than non-specific regulatory T cells. Sm-specific regulatory T cells for lupus nephritis Another group developed CD19-directed CAR regulatory T cells that suppressed autoantibody production and improved immune-cell balance in a humanized SLE model. CD19 CAR regulatory T cells in SLE

A related preclinical platform, chimeric autoantibody receptor T cells (CAAR-T cells), attempts to kill only B cells making particular pathogenic antibodies rather than eliminating most B cells. Investigators designed DNA-related CAAR-T cells to target anti-double-stranded-DNA-reactive B cells from people with lupus nephritis; in cell cultures and a kidney-organoid model, the lead construct reduced target B cells and protected organoid structure. DNA-targeted CAAR-T cells for lupus nephritis Such precision could eventually reduce infection risk and preserve normal antibody responses, but it has not yet been tested in people.

Clinical Trials and Experimental Approaches

Several CAR-cell platforms have progressed from compassionate-use treatment to formal trials. The published CASTLE study, led at Universitätsklinikum Erlangen, is a phase 1/2a trial of autologous anti-CD19 CAR-T cells in severe refractory systemic autoimmune disease. CASTLE phase 1/2 trial In China, a phase 1 trial of relmacabtagene autoleucel in eight adults with moderately to severely active SLE reported rapid reductions in disease activity, with four DORIS remissions and seven participants reaching low disease activity. Relma-cel phase 1 SLE trial The dual CD19/BCMA phase 1 study has provided the strongest published evidence to date that targeting long-lived plasma cells in addition to B cells may deepen remission. Dual CD19/BCMA CAR-T phase 1 trial

The field is now beginning to test CAR-T therapy against standard care in larger studies. Novartis is sponsoring a recruiting, randomized phase 2 trial of rapcabtagene autoleucel (YTB323) versus standard care in 144 adults with active, refractory lupus nephritis; its primary follow-up period is planned for up to five years. Novartis phase 2 YTB323 lupus-nephritis trial Cabaletta Bio’s RESET-SLE study is a recruiting phase 1/2 trial of rese-cel, an autologous CD19 CAR-T therapy for active SLE. RESET-SLE trial record Bristol Myers Squibb is also studying CD19-targeted Nex-T CAR-T cells in the phase 1 BREAKFREE-1 trial for severe refractory autoimmune diseases, including SLE. BREAKFREE-1 trial record

Not all experimental immune-resetting treatments use T cells. Nkarta’s Ntrust-1 trial is evaluating NKX019, an allogeneic, donor-derived CD19 CAR natural-killer-cell therapy, in lupus nephritis. Natural-killer cells may offer an “off-the-shelf” alternative to patient-specific CAR-T manufacturing, but this remains a phase 1 safety and dose-finding study. Ntrust-1 CAR-NK lupus-nephritis trial

Methodologies and Scientific Approaches

Clinical CAR-T studies typically use leukapheresis to collect a patient’s T cells, viral-vector gene transfer to add a synthetic receptor, laboratory expansion, lymphodepleting chemotherapy with fludarabine and cyclophosphamide, and a single CAR-T infusion. Researchers then track CAR-T expansion and persistence, B-cell depletion and recovery, immunoglobulin concentrations, autoantibodies, infections, cytokine-release syndrome, kidney function, proteinuria, and validated lupus outcomes such as DORIS remission and Lupus Low Disease Activity State. CD19 CAR-T case series Dual CD19/BCMA CAR-T phase 1 trial

Preclinical cure research increasingly combines patient-derived immune cells with humanized mouse models, kidney organoids, flow cytometry, autoantibody measurements, T-cell-receptor sequencing, and single-cell transcriptomics. These tools help researchers identify which immune-cell subsets drive kidney injury, match therapies to biomarkers, and test whether a candidate treatment suppresses disease without broadly damaging protective immunity. Sm-specific regulatory T cells for lupus nephritis DNA-targeted CAAR-T cells for lupus nephritis

Leading Institutions and Funding

Universitätsklinikum Erlangen in Germany, led by investigators including Georg Schett and colleagues, produced the first influential clinical reports of CD19 CAR-T therapy in refractory SLE and continues to lead the CASTLE program. First anti-CD19 CAR-T study in refractory SLE CASTLE phase 1/2 trial Other important clinical and translational contributors include RenJi Hospital in China, Novartis, Cabaletta Bio, Bristol Myers Squibb, and Nkarta. Relma-cel phase 1 SLE trial Novartis phase 2 YTB323 lupus-nephritis trial BREAKFREE-1 trial record

Funding is expanding alongside the science. NIH’s Research, Condition, and Disease Categorization system estimated $148 million in lupus research support for fiscal year 2025. NIH categorical funding data The Lupus Research Alliance reported investing nearly $12.9 million in innovative lupus research during 2024, including support for engineered-cell-therapy research, and the NIH launched its first cross-agency autoimmune-disease research strategic plan in July 2025 for fiscal years 2026–2030. Lupus Research Alliance 2024 annual report NIH autoimmune-disease strategic plan

Strengths, Limitations, and Challenges

The major strength of CAR-cell research is the consistency of the early signal: several independent groups have reported profound B-cell depletion, marked falls in lupus activity, and periods of medication-free remission in people whose disease had resisted multiple prior therapies. CD19 CAR-T case series Dual CD19/BCMA CAR-T phase 1 trial The possibility that remission persists after B cells return supports the hypothesis that treatment may reset—not merely suppress—pathological immune memory. CD19 CAR-T case series

The limitations are equally important. Published studies remain small and mostly uncontrolled, enroll unusually severe and heavily pretreated patients, and have limited long-term follow-up relative to a lifelong disease. CASTLE phase 1/2 trial CAR-T treatment can cause cytokine-release syndrome, low blood-cell counts, infections, low immunoglobulin levels, and risks from lymphodepleting chemotherapy; it also requires specialized centers and complex manufacturing. CD19 CAR-T case series Key unanswered questions include the durability of remission beyond several years, whether damaged organs can recover, which patients should receive such intensive therapy, whether repeat dosing will be needed, and whether manufacturing can become affordable and broadly accessible.

Outlook and Future Directions

As of October 22, 2026, lupus is not cured, but the field has moved closer to a plausible one-time, durable immune-resetting treatment than at any earlier point. The next milestones are randomized phase 2 results—especially in lupus nephritis—long-term follow-up showing that drug-free remission persists without unacceptable infections or loss of vaccine protection, and evidence that less toxic, scalable approaches such as CAR-NK cells or antigen-specific regulatory T cells can match CAR-T efficacy. Novartis phase 2 YTB323 lupus-nephritis trial Ntrust-1 CAR-NK lupus-nephritis trial Until then, the most accurate conclusion is that CAR-cell therapy is a highly promising experimental route toward functional cure—sustained remission without ongoing lupus treatment—not a proven cure available in routine care.

References

Don't see your disease? Request a report